Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag FDA updates testosterone labels, removing heart risk warnings but adding alerts for blood pressure.

flag The FDA has made labeling changes for testosterone therapies based on the TRAVERSE trial, which showed no increased cardiovascular risk compared to a placebo. flag The updated labels will remove previous warnings about cardiovascular risks but will add new warnings about increased blood pressure risks. flag The "Limitation of Use" language for age-related conditions will remain.

5 Articles

Further Reading